| 000 | 01804 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514163653.0 | ||
| 264 | 0 | _c20040415 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a0193-1849 | ||
| 024 | 7 |
_a10.1152/ajpendo.00373.2003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaeda, Seiji | |
| 245 | 0 | 0 |
_aEndothelin receptor antagonist reverses decreased NO system in the kidney in vivo during exercise. _h[electronic resource] |
| 260 |
_bAmerican journal of physiology. Endocrinology and metabolism _cApr 2004 |
||
| 300 |
_aE609-14 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBody Weight _xdrug effects |
| 650 | 0 | 4 | _aEndothelin A Receptor Antagonists |
| 650 | 0 | 4 | _aEndothelin Receptor Antagonists |
| 650 | 0 | 4 |
_aEndothelin-1 _xphysiology |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aKidney _xenzymology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 |
_aNitric Oxide _xphysiology |
| 650 | 0 | 4 |
_aNitric Oxide Synthase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aNitric Oxide Synthase Type III |
| 650 | 0 | 4 |
_aOrgan Size _xdrug effects |
| 650 | 0 | 4 |
_aPhysical Exertion _xphysiology |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aReceptor Cross-Talk _xdrug effects |
| 650 | 0 | 4 |
_aSulfonamides _xpharmacology |
| 700 | 1 | _aMiyauchi, Takashi | |
| 700 | 1 | _aIemitsu, Motoyuki | |
| 700 | 1 | _aTanabe, Takumi | |
| 700 | 1 | _aGoto, Katsutoshi | |
| 700 | 1 | _aYamaguchi, Iwao | |
| 700 | 1 | _aMatsuda, Mitsuo | |
| 773 | 0 |
_tAmerican journal of physiology. Endocrinology and metabolism _gvol. 286 _gno. 4 _gp. E609-14 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1152/ajpendo.00373.2003 _zAvailable from publisher's website |
| 999 |
_c14398416 _d14398416 |
||